Institutional equity research analysts covering Tiziana Life Sciences (TLSA) have published consensus price targets reflecting significant potential upside from its current micro-cap trading levels, with average one-year targets spanning around $9.00 to $9.18 per share. These optimistic projections are contingent upon continued clinical validation of its intranasal foralumab pipeline, successful regulatory milestones, and broader commercial partnerships within the biotechnology sector.